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Studies in cell-culture systems and in postmortem tissue from human disease have suggested a connection between cell-cycle activation and
neurodegeneration. The fruit fly Drosophila melanogaster has recently emerged as a powerful model system in which to model neurodegenerative
diseases. Here we review work in the fly that has begun to address some of the important questions regarding the relationship between cell-cycle
activation and neurodegeneration in vivo, including recent data implicating cell-cycle activation as a downstream effector of tau-induced
neurodegeneration. We suggest how powerful research tools in Drosophila might be utilized to approach fundamental questions that remain.
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Invertebrate model1. Introduction
In 1992, a report by Feddersen, Orr and colleagues showed
that SV40-mediated disruption of the tumor suppressor pRb
leads to Purkinje cell degeneration [1]. In an insightful
perspective piece that followed this study, Nathaniel Heintz
postulated that there may be a fundamental relationship between
neurodegeneration and neoplastic transformation and that
“genes that can cause transformation in dividing cell popula-
tions (and thus result in clonal expansion and neoplastic
disease) can cause programmed cell death of terminally
differentiated neurons (and thus result in clonal elimination
and neurodegenerative disease)” ([2]; Fig. 1). In the last decade,
an important body of work in cell-culture systems and in
postmortem tissue from human disease has further raised the
possibility of a mechanistic connection between transformation
and neurodegeneration [3]. There have, for example, been
several studies indicating that posmitotic neurons abnormally
re-express numerous cell-cycle markers and replicate their DNA
in neurodegenerative disorders, including tauopathies and
Alzheimer's disease (AD) [4,5]. In various neurotoxic para-⁎ Corresponding author. Tel.: +1 617 525 4405; fax: +1 617 525 4422.
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doi:10.1016/j.bbadis.2006.10.007digms in cell-culture systems, neuronal apoptosis can be
prevented by blocking various components of the cell-cycle
machinery [3]. Finally, certain cell-cycle regulators, including
E2F and Cdc2, have been shown to directly activate the
neuronal apoptotic machinery [6–9].
For all their strengths, studies associating aberrant cell-cycle
marker expression with neurodegeneration in postmortem tissue
have been largely correlative. For example, immunostaining in
these studies has often only been in abnormal structures such as
neurofibrillary tangles (NFTs), proteinaceous aggregates of the
microtubule-associated protein tau that could potentially bind
antibodies non-specifically. Also, proteins expected to be
nuclear during cell-cycle progression have sometimes been
found to be cytoplasmic in dying neurons [10,11]. Thirdly, both
cell-cycle activating and inhibitory proteins are upregulated in
AD and animal models [11,12], making it difficult to conclude
whether activation or inhibition of the cell cycle, or neither,
contributes to neuronal demise. These findings raise the
concerns that either aberrant cell-cycle marker expression
indicates nothing more than dysregulated protein synthesis in
dying neurons or, alternatively, that the upregulated proteins
may be subserving non cell-cycle roles. In this regard, Herrup
and colleagues made a significant advance by showing that
DNA is actually replicated in susceptible and dying neuronal
populations in AD, supporting the idea that neurons re-enter a
Fig. 1. Schematic diagram contrasting different consequences of cell-cycle
activation for proliferating and postmitotic cells. In this scheme, postmitotic
neurons forced to re-enter a cell cycle undergo apoptosis rather than cell
division.
Fig. 2. Simplified representation of cell-cycle regulators in mammalian (blue)
and Drosophila (black) cells. Positive regulators that facilitate progression are
boxed in green and negative regulators that inhibit progression are indicated in
red. The cell cycle consists of an S-phase (in which DNA is replicated) and an
M-phase (in which mitosis occurs), separated by two gap phases G1 and G2. G0
is a resting phase and is the phase which postmitotic neurons are considered to
occupy after differentiation. Cyclin-dependent kinases (Cdks) form complexes
with cyclins and regulate progression through the G1, S, G2 andM-phases of the
cell-division cycle. The E2F transcription factors and pocket proteins of the
retinoblastoma family (pRb) help coordinate the G1/S transition. The Cip
inhibitor Dacapo is the fly homolog of the Cip proteins p21/p27 and inhibits the
G1/S transition. In Drosophila, Cdk1/CyclinA catalyzes the G2/M transition
and Cdk1/CyclinB and Cdk1/Cyclin B3 catalyze progression through mitosis.
The phosphatase Cdc25 is a positive cell-cycle regulator, dephosphorylating and
activating key enzymes including Cdk1 and Cdk2 [23,34]. In vertebrate and
Drosophila cell cycles, PCNA is predominantly an S-phase marker and
phosphorylation at Ser-10 of Histone-3 (PH3) accompanies condensation of
chromosomes during M-phase.
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complexity, DNA replication and abnormal cell-cycle marker
re-expression in postmitotic neurons has been described in
several animal models in which neurons do not appreciably
degenerate, including rodent models of ATM [13] and AD [14],
and in Retinoblastoma Protein-1 (pRb-1)-deficient mice. For
example, while widespread neurodegeneration occurs in the
central nervous system (CNS) of pRb-1-deficient mice [15,16],
this effect is non cell-autonomous because in chimeric mice, the
pRb-1 −/− clones in the CNS exhibit tetraploidy in the absence
of appreciable neuronal death [17].
Bearing these data in mind, we wondered first whether there
was a causal relationship between cell-cycle activation and
neurodegeneration in animal models of tauopathy and second,
whether cell-cycle activation was sufficient to cause neurode-
generation. Third, if cell-cycle activation did mediate neuronal
death, it remained to be seen which phase of the cell cycle was
lethal for a neuron. The absence of any description of mitotic
figures or cytokinesis of a postmitotic neuron certainly implied
that adult neurons could not progress through mitosis, although
studies in cell-culture systems also implicated early G1/S
mediators, such as E2F and Cyclin D, in causing neuronal
apoptosis. Finally, the question of the triggers for postmitotic
neuron to re-enter the cell cycle remained unknown. In
particular, in postmortem tissue from AD, numerous mitogenic
signaling molecules had been shown to be upregulated [18–22],
but the consequences of these pathways being activated in
postmitotic neurons, whether apoptotic or pro-mitotic, were
unclear.
In this context, we felt the genetically tractable fruit fly, in
which neurodegenerative diseases are now modeled, had a
unique role to play. In this review, we highlight the utility of this
model organism to investigate the connection between cell-
cycle activation and neurodegeneration. We analyze recent
experimental data that have begun to address some of the
important questions in the field, and discuss how methods in the
fly might be utilized to approach fundamental questions that
remain.
2. The utility of Drosophila in investigating the
cell-cycle/neurodegeneration connection
Drosophila is ideally suited to investigate the relationship
between neurodegeneration and cell-cycle activation in vivo forseveral reasons. First, the cell-cycle machinery is substantially
conserved between Drosophila and mammalian systems [23].
Indeed, considerable advances in our understanding of the role
of cell-cycle mediators in vivo have been afforded by
investigations in flies. Second, there are now several well-
established Drosophila models of neurodegeneration, including
tauopathies, Parkinson's disease (PD) and polyglutamine
disorders (reviewed in [24]). As noted above, postmortem
analyses associate cell-cycle activation with tauopathies
including AD. Of primary importance, the relative low level
of redundancy in the fly genome (that is, a single gene in
Drosophila is often the only homolog for an entire family of
mammalian genes) and the availability of many sophisticated
genetic tools make genetic analysis in Drosophila well suited to
address issues of causality. Finally, the short lifespan and
reproductive cycle of flies allow for the analysis of many
potential genetic modifiers in a relatively short amount of time.
2.1. Cell-cycle and mitogenic signaling machineries are well
conserved in Drosophila
In the cell cycle, DNA synthesis occurs during S-phase and
mitosis occurs inM-phase. Two gap phases (G1 and G2) separate
the S- and M-phases. Between division cycles, cells are in G0.
Neurons are generally considered postmitotic and permanently in
G0 (Fig. 2). Immunohistochemical markers can be used to
identify cell-cycle phases. For example, the proliferating cell
nuclear antigen (PCNA), thought to function as a “sliding clamp”
for DNA polymerase-δ [25], is upregulated during G1, S and G2.
Phosphorylation at Ser10 of Histone-3 (PH3) occurs during
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considered an M-phase-specific marker. It should be noted,
however, that these markers are upregulated in situations other
than cell division—for example, PCNA is involved in DNA
repair [27] and phosphorylation of Histone-3 at Ser10 occurs
during immediate-early gene transcription [28]. 5-bromo-2′-
deoxyuridine (BrdU) incorporation into actively synthesized
DNA is a more definitive S-phase marker than PCNA.
Cyclin-dependent kinases (Cdks) catalyze reactions essential
for progression through the cell cycle. Key regulators of the G1/
S checkpoint include the E2F family of transcription factors, the
pocket proteins (including pRb) and the Cdk inhibitors p21 and
p27 (Fig. 2). E2F1 and E2F2 can directly activate the
transcription of many S-phase genes, including DNA polymer-
ase-α and Cyclin E [29]. Pocket proteins of the pRb family can
directly bind and inhibit E2F-mediated transactivation [30].
This inhibition is relieved by pocket protein phosphorylation by
Cdks. Alternatively, E2F4 and E2F5 can bind pocket proteins
and form complexes that repress transcription. p21 and p27
regulate the G1/S transition by directly binding and inhibiting
Cdk2/Cyclin E. These inhibitors can also inhibit DNA synthesis
by binding PCNA [31].
In Drosophila, the essential features of the cell cycle are
conserved [23]. Homologs of Cdks, Cyclins, Cip inhibitors,
E2F transcription factors and pocket proteins have been
described [32]. Drosophila homologs are indicated in Fig. 2
(black). Cdk1 and Cdk2 are often referred to in the literature as
cdc2 and cdc2c, respectively. Note that Drosophila Cyclin A
complexes with Cdk1 but does not complex with Cdk2. Cyclin
E, however, does complex with Cdk2 to facilitate the G1/S
transition. The G2/M transition is dependent upon Cdk1/Cyclin
A in flies, with Cdk1/Cyclin B complexes thought to be
important in progression through the various stages of mitosis.Fig. 3. Drosophila model of tauopathy. (A–D) The tau-induced rough eye phenotype
degeneration. Compare the elav-GAL4/+ (A) and GMR-GAL4/+ (C) control eyes wit
elav-GAL4/+; UAS-tauR406W6/+) or tauV337M (D; genotype: UAS-tauV337M1/+; GMR
eosin-stained frontal section through the head and brain of a wild-type fly. (F–G) Are
(F) and mutant tau-expressing (G) flies. Vacuolization is observed in the nerve fibre
known as the cortex (arrow). (H) Bipartite UAS/GAL4 system: This system allows fo
with elav-GAL4, or in the Drosophila eye with elav-GAL4 (photoreceptors only) or
with permission from [42].The fly homolog for p27/p21 is Dacapo (Dap)[33]. There are
two E2f family members in Drosophila [34]. E2f1 directly
transactivates gene transcription, like the vertebrate E2Fs 1/2/3,
and is inhibited by Rbf, the homolog of pRb-1. E2f2, like the
vertebrate E2Fs 4/5, forms repressor complexes with Rbf2. In
studies of Drosophila development, inhibition of the G1/S
transition is achieved by overexpressing Rbf1, dE2f2, Rbf2,
Dacapo or human p21 [33,34]. The G1/S transition appears to
be most effectively inhibited in the developing larval eye disc
by co-expressing both Dap and Rbf1 [33].
The primary function of Cdk4/Cyclin D during fly develop-
ment appears to be as a growth activator, although Cdk4/Cyclin
D drives the G1/S transition indirectly in some tissues [35,36].
Similarly, classic mitogenic and oncogenic signaling pathways,
including Myc [37], Ras [38] and TOR [39], are highly
conserved in flies and appear to drive the G1/S transition
indirectly by promoting cellular growth. Interestingly, several
papers have shown that TOR activity is abnormally upregulated
in AD brain [18,40].
2.2. A Drosophila model of tauopathy
In postmortem studies, early cell-cycle markers including
PCNA are upregulated in a number of acute and chronic
neurodegenerative conditions [6]. In contrast, markers of the
G2/M transition appear to be more selectively upregulated in
tauopathies [4]. Tauopathies are neurodegenerative diseases
characterized by intraneuronal accumulations of hyperpho-
sphorylated forms of the microtubule-associated protein tau.
The term encompasses hereditary frontotemporal dementia and
parkinsonism linked to chromosome 17 (FTDP-17), and
sporadic tauopathies including AD, progressive supranuclear
palsy and Pick's disease. We, and others, have developedconsists of a small irregular eye with fused ommatidia and small focal areas of
h eyes of transgenic flies expressing mutant forms of tau, tauR406W (B; genotype:
-GAL4/+). This phenotype is visible in adults at eclosion. (E) Hematoxylin and
as of the fly brain similar to that boxed in (G) are shown for control elav-GAL4/+
layer known as the neuropil (N, arrowheads) and in the neuronal cell body layer
r specific expression of tau either in postmitotic neurons, including the fly brain,
GMR-GAL4 (photoreceptors and support cells). F and G have been reproduced
Table 1
Cell-cycle mediators tested for modification of tau-induced neurodegeneration
phenotypes
Cell-cycle mediator System* Interaction with tau **
UAS-Dacapo/UAS-Rbf1 Ret, Br Sup
UAS-Dacapo/UAS-Cdk1DN Ret, Br Sup
Cyclin ALOF Ret Sup
Cyclin BLOF Ret Sup
Cyclin B3LOF Ret Sup
E2f1LOF Ret Sup
Cyclin DLOF Ret Sup
Cdk4LOF Ret Sup
Cyclin ELOF Ret None
UAS-Cyclin A Ret, Br Enh
UAS-Cyclin B Ret, Br Enh,(Ret), Lethal (Br)
UAS-Cyclin B3 Ret, Br Enh,(Ret), Lethal (Br)
UAS-Cdk1, UAS-Cyclin B Ret, Br Enh,(Ret), Lethal (Br)
UAS-Cdk4, UAS-Cyclin D Ret, Br Enh,(Ret), Semilethal (Br)
UAS-Cyclin E Ret, Br Enh(Ret), Lethal (Br)
UAS-Cdk1 Ret None
UAS-Cdk2 Ret None
* Retina (Ret; driver: GMR-GAL4), Brain (Br; driver: elav-GAL4).
** Synergistic Enhancement (Enh), Suppression (Sup) of tau-induced
neurodegeneration, No effect (None),Lethal/Semilethal combination when co-
expressed (Lethal, Semilethal). Abbreviations: Dominant negative (DN), Loss-
of-function allele (LOF); UAS (Upstream Activating Sequence) refers to GAL4-
responsive transgenes. Bold face indicates unexpected interactions. Information
regarding specific genetic reagents is published [46] or is available from the
authors by request.
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created by expressing human wild-type or FTDP-17-associated
mutant tau constructs. Tissue-specific expression of the
transgenes is achieved using the bipartite UAS/GAL4 system
derived from yeast [43]. For example, GMR-GAL4 drives
expression within retinal tissue, in both neuronal (photorecep-
tors) and non-neuronal postmitotic cells. elav-GAL4 drives
transgene expression within postmitotic neurons, including
photoreceptors of the retina and the brain (Fig. 3H).
Tau expression induces retinal and brain phenotypes that
have been well characterized in our laboratory and by other
investigators [41,42,44]. Retinal toxicity is observed in adult
flies as a “rough” eye phenotype. The eye is reduced in size,
loses its regular ommatidial structure and is irregularly
contoured (Fig. 3A–D). The rough eye phenotype is useful
because it is easily scored and amenable to genetic modifica-
tion, making it a valuable tool for both forward (unbiased) and
candidate genetic screens. Recently, this phenotype was used to
conduct a P element-based forward modifier screen for tau-
induced neurotoxicity [45].
When tau is expressed with elav-GAL4, adult flies eclose
with morphologically normal brains. However, in adult life,
accumulation of disease-associated phospho- and conforma-
tional tau epitopes accompanies progressive neurodegeneration,
histologically characterized by neuronal nuclear fragmentation
and vacuolization of the cortex and neuropil (Fig. 3 F, G)
[42,44], and TUNEL (terminal transferase-mediated deoxy-
UTP biotin nick end-labeling) staining of apoptotic neurons
[46].
3. Investigating cell-cycle activation in a Drosophila
tauopathy model
3.1. Establishing a causal connection between tau-induced
neurodegeneration and cell-cycle activation in vivo
Recently, we found that, as in tauopathies, the cell-cycle
markers PCNA and PH3 were abnormally expressed in neurons
in the Drosophila tauopathy model [46]. These could always
be found in transgenic tau fly brains, but were completely
absent in age-matched control flies. PCNA staining was both
cytoplasmic and nuclear, and PH3 staining was entirely
nuclear, consistent with the subcellular localization patterns
during cell-cycle activation. In agreement with previous
postmortem and cell-culture studies, we did not see abnormal
cytokinesis of postmitotic neurons in the brains of transgenic
tau flies.
A comprehensive genetic analysis in the retina and brain
(Table 1) established a clear causal relationship between cell-
cycle activation and neurodegeneration. In other words, the use
of mutant alleles or transgene combination to inhibit cell-cycle
progression substantially reduced tau-induced neuronal apop-
tosis. In contrast, co-expressing genetic activators of the cell-
cycle synergistically enhanced tau-induced neurodegeneration.
Cdk1 and Cdk2 enhanced tau-induced neurodegeneration
when co-expressed with their respective Cyclins. Since multiple
reagents at both the G1/S and G2/M transition fitted this pattern,our data strongly implicated the cell-cycle pathway as a whole
in mediating tau-induced neurodegeneration. There were rare
exceptions to the rule. For example, two separate Cyclin E
mutants did not suppress tau-induced retinal degeneration. This
may be trivially related to haplosufficiency of Cyclin E.
Notably, however, these alleles do exert dominant effects in
developmental contexts [47] and, overall, the effects of
modulating the G2/M Cyclins A and B were certainly more
striking in modifying tau-induced toxicity than the effects of
modulating the G1/S Cyclins D and E.
Postmortem analyses of AD and tauopathy tissue have
associated cell-cycle marker expression with abnormal tau
phosphorylation. Since Cdks are well known to phosphorylate
tau [48], the question of whether cell-cycle activation acts up- or
downstream of tau phosphorylation remained an important open
question amenable to genetic analysis. In the fly tauopathy
model, reducing tau phosphorylation genetically, by reducing
the level of a known tau kinase glycogen synthase kinase-3
(GSK-3), led to decreased cell-cycle activation. Conversely, a
pseudophosphorylated tau construct exhibited dramatically
increased toxicity and commensurately increased ectopic cell-
cycle marker expression in the brain. Furthermore, the toxicity
induced by this pseudophosphorylated construct was blocked
by cell-cycle inhibition. Finally, immunohistochemical data
indicated that only a small subset of neurons containing
abnormally phosphorylated tau were immunopositive for cell-
cycle markers [46]. Taken together, these experiments indicated
that cell-cycle activation occurred downstream of abnormal tau
phosphorylation in the fly model. In our view, these experi-
ments exemplify the utility of simple genetic models in casting
Fig. 4. Potential mechanisms for tau-induced cell-cycle activation. These
include general mechanisms, such as DNA damage [67,88,89], oxidative stress
[66] and dysfunction of the ubiquitin–proteasome system [80]. Other
mechanisms may be tau-specific, including direct-tau protein interactions that
subserve activation of mitogenic signaling pathways, and indirect activation of
the cell cycle through alterations of microtubules.
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in other model systems, or in human postmortem tissue
analysis. Of course, the findings in the fly model do not rule
out alternative mechanisms operating in mammalian models or
in human disease.
Since cell-cycle activation occurred downstream of abnor-
mal tau phosphorylation in the fly tauopathy model, cell-cycle
activation might directly precede apoptosis [46]. We tested
whether ectopic cell-cycle activation was sufficient to trigger
apoptosis by using elav-GAL4 (or the inducible GeneSwitch-
elav) drivers to express E2f1/Dp, Cdk2/Cyclin E and Cyclin A
in neurons. We found that increased TUNEL staining
accompanied upregulation of PCNA and PH3, indicating that
ectopic cell-cycle activation is sufficient to trigger neuronal
apoptosis. Ectopic E2f1/Dp expression, in particular, lead to
dramatic neuronal apoptosis and cell loss commensurate with
the degree of cell-cycle marker upregulation. It should be noted,
however, that these experiments do not rule out potential cell-
cycle-independent apoptotic effects of ectopic cell-cycle
activation. For example, E2f1/Dp is known to directly
transactivate proapoptotic genes in cell-culture system and in
flies [49]. Interestingly, our preliminary data indicate that
cyclins vary in their efficacy to induce apoptosis, and that
different neuronal populations within the brain respond
differently to the same cell-cycle stimulus.
3.2. Determining the link between tau and cell-cycle re-entry
Having established a causal relationship between cell-cycle
activators and tau-induced neurodegeneration, we focused on
the mechanism of tau-induced cell-cycle activation. Potential
mechanisms include those more closely related to tau, both in
terms of its role as a microtubule-associated protein and its
amino acid sequence, and general mechanisms, including
oxidative stress, DNA damage and inhibition of the ubiquitin/
proteasome system (Fig. 4). The general mechanisms each have
precedents in cell-culture systems. Our data indicated that
ectopic cell-cycle marker expression was not a feature of the PD
and spinocerebellar ataxia-3 (SCA3) fly models, and cell-cycle
modification did not modify the SCA3-induced retinal
phenotypes, supporting the possibility that cell-cycle activation
may be tau-specific [46].
Intriguing data from cell-culture systems implicate tau as a
potential signaling molecule. Tau has been identified at the cell
membrane and is enriched in axon growth cones. Furthermore,
transfection of tau into neuronal cell lines results in neurite
extension, suggesting that tau is capable of activating complex
and coordinated intracellular signals [50,51]. Tau is well known
to be phosphorylated at many disease-associated phosphoepi-
topes in fetal life [52], a period of dynamic growth cone
changes, and tau-induced neuritic extension in cell culture
studies is modulated by Ser-Pro/Thr-Pro phosphorylation [50].
Phosphorylated tau may thus be particularly effective at
transducing growth signals, a finding that may have relevance
for disease states in which tau is hyperphosphorylated. As noted
above, tau phosphorylation was required for tau-induced cell-
cycle activation in the fly tauopathy model.The amino acid sequence of tau reveals 5 tyrosines, 7 N-
terminal PXXP motifs and multiple SP/TP motifs (Fig. 5). Since
SH2 domains bind phosphotyrosine, SH3 domains bind
proline-rich domains that commonly contain a “PXXP” motif
and WW domains bind SP/TP motifs, tau could potentially bind
proteins containing these modular domains and be capable of
transducing complex signals through binding multiple regula-
tory and adapter proteins. The receptor tyrosine kinases (RTKs),
including the platelet-derived growth factor receptor, are classic
example of such molecules. RTKs have tyrosine kinase catalytic
function but contain multiple tyrosines that, when phosphory-
lated, bind SH2 domain-containing proteins including the
adapter protein PLC-γ and Src family tyrosine kinases. Such
interactions serve to amplify mitogenic signals by providing
additional docking sites for modular signaling proteins.
Hyperactive RTK signals can lead to oncogenesis through
multiple mechanisms including increased transcription and
translation of necessary components for growth and prolifera-
tion [53]. Viral antigens, such as the large and small SV40 T
antigens, are other examples of proteins involved in multiple
interactions, including with pRb, protein phosphatase 2A
(PP2A) and p53, that induce cellular transformation [54]. In
fact, the literature reveals that tau also binds several SH2/SH3
and WW domain-containing proteins, including non-receptor
tyrosine kinases of the Src-family and c-Abl, the prolyl
isomerase Pin-1 and phospholipase C-γ (PLC-γ) (Fig. 5). An
intriguing association has recently been described between the
Fig. 5. Tau as a signaling molecule. Tau contains 14 SP/TP, 5 tyrosines (at least
two of which – Y18 and Y394 – are known to be phosphorylated in PHF-tau),
and 7 PXXP-type motifs, making it a potential binding partner for WW, SH2 and
SH3 domain-containing proteins, respectively. In cell culture and in vitro
systems, tau is known to bind to SH2/3-containing proteins including Src
family non-receptor tyrosine kinases [51], c-Abl [90] and PLC-γ [91,92].
Binding of tau to the Fyn-SH3 domain occurs at the PXPXXP sequence shown
(232–236). Tau also binds the WW domain-containing protein Pin-1, which
isomerizes P-Thr-231 to render it more readily dephosphorylated by PP2A [93].
Other candidate proteins of interest, with genetic reagents available in flies,
include the WW domain-containing proteins hWW-45 and Itch and the SH2/
SH3-containing RASGAP. Note that fly homologs are labeled in black.
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1 blocks both pRb-1 function in human cell lines by competing
for HDAC binding [56]. The direct binding between tau and a
negative regulator of the cell cycle is of obvious interest in the
context of investigating the connection of tau to the cell cycle.Fig. 6. TOR signaling in Drosophila [94–96]. TOR integrates nutrient availability wi
receptor is a ∼ 400 kDa tyrosine kinase receptor. PI3K is activated by direct recruitm
systems, a well-characterized mechanism of PI3K activation is through Ras. PI3K a
appear to be the case in flies [96]. However, signaling from PI3K to Akt, and to TOR
inhibitory for the Rheb GTPase [98]. Rheb activates TOR and drives growth and ind
downregulates TOR signaling [102]. The two major downstream effectors are S6k
inhibited by 4EBP and TOR-dependent phosphorylation of 4EBP relieves this inhibit
other systems. Studies in mammalian cell-culture systems have demonstrated tha
biogenesis. eIF4E activates Cap-dependent protein translation. Targets may include
Myc [104].Interestingly, tau is a substrate of the neuronally enriched PP2A
and PP2A activity is decreased in AD [57–60].
Since fly homologs for classic oncogenic signaling pathways
and known tau interactors exist, we tested many signaling
molecules for genetic modification of the tau-induced rough
eye. Our candidate analysis is ongoing, but has hitherto strongly
implicated signaling pathways known to activate growth as
mediators of tau-induced neurotoxicity. Since the TOR pathway
is a point of convergence for multiple growth-activating
pathways (Fig. 6; [61]) and TOR signaling has been linked to
aging [62,63] and AD [18], we thoroughly investigated the
effect of modulating this pathway on tau-induced neurodegen-
eration [46]. We consistently found that TOR-activated genetic
backgrounds synergistically enhanced tau-induced neurotoxi-
city, and TOR inhibition ameliorated tau-induced neurodegen-
eration in the retina and brain (Table 2). Our data indicated that
TOR-dependent enhancement of tau-induced neurodegenera-
tion could be blocked by concomitant cell-cycle inhibition and
that ectopic TOR activation induced aberrant neuronal cell-
cycle marker expression and apoptosis. These data strongly
implicate TOR as an important mediator of tau-induced cell-
cycle activation, although do not rule out parallel pathways
existing for tau-induced cell-cycle activation.
4. Fundamental questions that remain and how Drosophila
might help
The Drosophila tauopathy model has proved useful in
resolving three issues to date. First and foremost, a causalth signals from multiple pathways, including insulin signaling/PI3K. The insulin
ent to the insulin receptor substrate (IRS; also known as Chico). In mammalian
ppears to activate MAP kinase pathways in mammalian cells, but this does not
is well conserved. Akt phosphorylates and inhibits Tsc2 [97], the GAP protein
irectly the G1/S transition [99–101]. Over-expressing TOR itself paradoxically
and eIF4e. In flies, TOR activates S6k by phosphorylating Thr398. eIF4E is
ion, leading to protein translation [103]. Thin arrows indicate links established in
t S6K phosphorylates the ribosomal protein S6 and thus activates ribosome
Cyclin D and the Myc oncogene [61]. eIF4e is in turn a transcriptional target of
Table 2
TOR-signaling mediators tested for modification of tau-induced neurodegeneration
phenotypes
TOR signaling mediator System * Interaction with tau **
TORLOF Ret Sup
RhebLOF Ret Sup
S6kLOF Ret Sup
eIF4eLOF Ret Sup
UAS-4ebpGOF Ret None
UAS-Tsc1 Ret Sup
UAS-Tsc2 Ret Sup
UAS-Tsc2GOF Ret Sup
UAS-TOR Ret None ***
UAS-Rheb Ret, Br Enh (Ret), Lethal (Br)
UAS-Tsc2LOF Ret Enh
* Retina (Ret; driver: GMR-GAL4), Brain (Br; driver: elav-GAL4).
** Synergistic Enhancement (Enh), Suppression (Sup) of tau-induced
neurodegeneration, No effect (None), Lethal combination when co-expressed
(Lethal).
*** Overexpression of TOR is known to paradoxically cause a loss-of-function
phenotype during development [102]. Overexpression of the Rheb GTPase,
however, activates the pathway [99,100]. Abbreviations: Dominant negative (DN),
Loss-of-function allele (LOF), Gain-of-function/constitutively active allele (GOF);
UAS (UpstreamActivating Sequence) refers to GAL4-responsive transgenes. Bold
face indicates unexpected interactions. Information regarding specific genetic
reagents is published [46], or is available from the authors by request.
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activation and tau-induced neurodegeneration in vivo. Second,
in the fly model, genetic manipulations and the use of different
tau constructs has been useful in determining the epistasis of tau
phosphorylation to cell-cycle activation. Our data would
indicate that tau phosphorylation is upstream of cell-cycle
activation. Third, we have shown that TOR signaling is required
for tau-induced neurodegeneration and that TOR can ectopi-
cally activate cell cycle-dependent neuronal apoptosis in vivo.
Fundamental questions remain more open, however, and these
will be discussed in turn.
4.1. “Cell-cycle activation” in neurodegeneration: do we mean
a coordinated cell cycle or cell-cycle mediator-dependent
apoptosis?
Our genetic analyses in the tauopathy model indicate that
activation of cell-cycle mediators is necessary for tau-induced
neurodegeneration, since numerous manipulations at both the
G1/S and G2/M checkpoints with multiple genetic reagents
produce a consistent pattern of modification [46]. The presence
of both PCNA and PH3, markers of different cell-cycle phases,
supports the possibility that neurons may have re-entered a
coordinated cell cycle. Certainly, the absence of any evidence of
cytokinesis in our model indicates that neurons cannot
successfully progress through mitosis. Our genetics would
also generally indicate stronger effects of modulating G2/M
cyclins on tau phenotypes than G1/S cyclins (see Section 3.1,
above), indirectly supporting neuronal apoptosis being trans-
duced later in the cell cycle. We cannot, however, rule out a
second possibility that positive cell-cycle regulators, including
Cdks and E2f1/Dp, are involved in transducing tau-induced
apoptosis in the absence of a coordinated cell-cycle progression.Studies in cell-culture systems have revealed that E2F family
transcription factors can directly transactivate pro-apoptotic
genes [9], and that Cdk1 can directly lead to BAD-dependent
neuronal apoptosis [8]. In contrast, postmortem tissue analyses
in AD and AD mouse models suggest that DNA has been
replicated in susceptible postmitotic neurons. Furthermore, in
cell-culture AD models, neuronal apoptosis can be blocked by
inhibiting DNA polymerase [3]. These latter investigations
would support a coordinated cell-cycle progression being
potentially responsible for neurodegeneration. The distinction
is biologically important because, in the former case, cell-cycle
activators are simply upstream components of the neuronal
apoptosis mechanism. In the latter case, cell-cycle processes,
the replication of DNA or the G2/M transition for example, may
be responsible for cell death.
The Drosophila tauopathy model may be useful in resolving
this issue, although more definitive measures of cell-cycle
phasing are required. Such techniques would include assays for
neuronal BrdU incorporation and FISH or fluorescence-
activated cell sorting (FACS) to directly assess neuronal ploidy.
BrdU incorporation [33,64] and FACS [35] are standard
techniques that have been used to determine the effect of cell-
cycle modulators in proliferating fly larval tissues. We have not
yet observed BrdU incorporation in the fly brain of transgenic
tau flies, although whether this is a true negative result or simply
reflects the technical limitations of the experiment remains
unclear. It is important to note that relatively few neurons in the
brain of transgenic tau flies demonstrate re-expression of cell-
cycle markers at any given time, and thus negative results from
any of these approaches would be difficult to interpret. An
alternative approach would be to express tau in proliferating
tissue, such as fly imaginal discs in which ploidy analysis is a
well-established technique. Coupled with FACS analysis, this
may provide interesting insights into how tau affects cell-cycle
phasing. Our preliminary data would suggest that tau expression
in imaginal discs does in fact lead to marked increases in cell-
cycle marker activation, indicating either hyperproliferation or
delayed cell-cycle exit.
4.2. Is neuronal cell-cycle activation sufficient to cause
neuronal apoptosis?
The question of sufficiency of cell-cycle activation for neuro-
nal apoptosis has plagued the cell-cycle/neurodegeneration field
since its inception with the observation that DNA replication can
be observed in the absence of neurodegeneration in a variety of
context in postmitotic neurons, including in Rb−/− chimeric
mice, Atm−/− mice, APP transgenic mice and in certain
populations of neurons in AD brain [5,13,14,17]. Our data
would indicate the ectopic expression of multiple cyclins and
E2f/Dp in the brain is sufficient to drive apoptosis of postmitotic
neurons in vivo [46]. Interpretation of these experiments,
however, is complicated by PCNA and PH3 being our only
available read-out for cell-cycle activation in the fly brain. Each
marker could, for example, represent multiple phases of the cell
cycle (PCNA: G1, S, G2; PH3: G2, M), a transcriptional
upregulation of cell-cycle regulators in the absence of co-
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response (PH3) or a response to DNA damage (PCNA).
Again, accurate determination of cell-cycle phasing in different
contexts may help resolve these issues because it may be that
neuronal apoptosis is transduced at the G2/M and not the G1/S
transition in vivo. It is possible that this is context-dependent and
dependent upon pathogenesis, or even variable among different
populations of neurons exposed to the stimulus. Indeed, in flies,
as described in Section 3.1, ectopic expression of different
cyclins leads to cell-cycle marker expression and apoptosis in
different neuronal populations.
Investigating the issue of sufficiency is important for several
reasons. First, understanding the phase at which the apoptotic
signal is transduced may have significant implications for
designing appropriate therapies. Also, events occurring up- or
downstream of tau-induced cell-cycle activation may be critical
for an apoptotic response once the cell cycle becomes activated
[65]. These events could also potentially be therapeutic targets.
Recently, it has been proposed that oxidative stress may be one
such critical upstream event [65,66]. For example, a neuron
might be able to enter an S-phase without detriment, unless its
DNA has previously been damaged. Thus, an attempt to
replicate damaged DNA may be the trigger for apoptosis rather
than cell-cycle re-entry itself [67], and oxidative stress may be
one important cause of such DNA damage. We have recently
showed that genetic and pharmacologic manipulation of
oxidative stress modifies tau-induced neurodegeneration in
flies (Dias et al., in press), and thus the fly tauopathy model may
be very useful in investigating the cell-cycle/oxidative stress
connection. Determining critical upstream events may also shed
light on the tau-induced phenotype itself because, while ectopic
TOR and cell-cycle activation can lead to neuronal apoptosis in
the fly brain, in neither situation is the tau phenotype precisely
recapitulated, suggesting that events occurring upstream of
TOR/cell cycle may be crucial determinants of this phenotype.
4.3. Are there critical non cell-autonomous factors that mediate
cell-cycle-dependent apoptosis?
An issue related to sufficiency of cell-cycle activation for
neuronal apoptosis is discerning cell-autonomous from non
cell-autonomous factors in the mediation of cell-cycle-depen-
dent neuronal death. Cell-cycle-dependent neuronal apoptosis
has generally been thought of as a cell-autonomous process, as
suggested by investigations in cell culture paradigms. However,
there may be critical non cell-autonomous contributors to this
process in vivo. The CNS phenotype of mice null for the tumor
suppressor pRb (pRb-1 −/−) is a striking example of such a
possibility. pRb-1−/− mice die in embryonic life (E13–E15)
with significant hematopoietic abnormalities and massive
apoptotic neuronal death in the central and peripheral nervous
system [15,16]. The appearance of the neuronal phenotype
temporally coincides with normal neuronal cell-cycle exit and
commencement of differentiation. Histologically, proliferation-
competent neurons in the ventricular zone of the neural tube are
normal but apoptotic and mitotic markers are found in CNS
regions usually populated by postmitotic cells. These findingsimply a role for pRb-1 in either establishing or maintaining the
postmitotic state, and possibly in neuronal differentiation.
Interestingly, more recent studies have indicated that central
neuronal apoptosis in pRb-1−/−mice is not cell-autonomous. In
chimeric mice, composed of wild-type and pRb-1−/− cells,
central (but not peripheral) neuronal apoptosis does not occur
despite the failure to achieve cell-cycle exit, indicated by
abnormal tetraploid cells. The cell-cycle profile, however, of
these neurons appear to be different because, while PH3-
staining and FACS analyses indicate that many CNS neurons
have entered late G2 or M phase in the germline pRb-1−/−
animals, neurons in the chimeric mice do not appear to enter M-
phase [17]. Surprisingly, the largely normal development of the
CNS in chimeras implies that tetraploid neurons are perhaps
even capable of differentiation. Thus, these results indicate that
apoptosis in this particular developmental context is non cell-
autonomous and that failure to exit the cell cycle is not sufficient
to trigger central neuronal apoptosis. The results also raise the
possibility that apoptosis is triggered at the G2/M checkpoint
and that non cell-autonomous factors are required to drive
neurons into late G2/M. Finally, the studies indicate important
differences between cell-death signaling in central and periph-
eral nervous system neurons. An intriguing recent study has
indicated that the critical non cell-autonomous factors that
trigger apoptosis in this model may be placentally derived since
pRb-1−/− mice grown in a wild-type placenta do not develop
CNS pathology [68,69].
Drosophila is an attractive model system in which to search
for potential non cell-autonomous factors in cell-cycle-depen-
dent neuronal death. For example, in addition to ectopic
neuronal expression of cyclins or E2f/Dp, it would be
interesting to introduce other genetic or environmental
manipulations, both within and outside the nervous system, to
determine factors that might modulate the neuronal response to
ectopic cell-cycle activation. Obvious candidates for such
manipulations would be oxidative stress, DNA damage and
cell-cycle checkpoint pathways, all of which have been
extensively characterized in a variety of contexts in flies
[70,71]. The modulation of molecules known to alter lifespan,
such as those in the insulin signaling pathway or Sir2, within the
brain and fat body might also be very interesting in this context
[72–74]. In addition, genetic tools are now available in flies to
facilitate creation and analysis of clones in the brain, allowing
ectopic activation of the cell cycle in a select group of neurons,
or in glial cells. It would be interesting if neuronal cell-cycle
activation can lead to non cell-autonomous death of surround-
ing neurons, potentially analogous to the non cell-autonomous
apoptosis that occurs in cells surrounding clones that have been
conferred a growth advantage. Several recent papers have been
published on this phenomenon of “super-competition” in clonal
analyses of developing fly imaginal discs [75,76].
4.4. How do the TOR/cell-cycle pathways become activated in
the Drosophila tauopathy model?
In Section 3.2, we outlined several possibilities for tau-
induced cell-cycle activation. As depicted in Fig. 4, these
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oxidative stress or DNA damage, inhibition of the ubiquitin–
proteasome system. Other mechanisms depicted were more
specifically related to tau, including direct tau–protein interac-
tions and altered microtubule dynamics. We have made good
progress in delineating signaling pathways, including TOR, that
mediate cell-cycle activation in our model. An important aim of
future studies will be to determine the mechanism whereby tau
activates mitogenic signaling pathways. In cell-culture systems,
oxidative stress activates numerous mitogenic signaling path-
ways [77] and fluctuations in redox potential may critically
regulate cell-cycle proteins [78]. As noted above (Section 4.2),
we have recently found that genetically and pharmacologically
modulating the oxidative stress response can modify tau-
induced neurodegeneration phenotypes (Dias et al., in press). In
fact, decreasing anti-oxidant defences in the fly brain does
potentiate tau's ability to induce cell-cycle marker re-expres-
sion, implicating oxidative stress in this process. Interestingly,
microtubule stabilization in proliferating can induce TOR-
dependent apoptosis [79]. It will be interesting to determine
whether direct manipulations of the microtubules, whether
genetic or pharmacologic, can recapitulate cell-cycle pheno-
types, Likewise, numerous genetic reagents are now available in
Drosophila to manipulate the UPS and thus the hypothesis that
defective degradation of mitotic cyclins leads to aberrant cell-
cycle activation [80] is readily testable in vivo in flies.
As mentioned in Section 3.2, tau is known to bind several
molecules involved in mitogenic signaling. Homologs of these
interacting proteins exist in flies and, in several cases, have been
well characterized. Future studies may help determine whether
genetic manipulations of these potential interactors alters tau-
induced neurodegeneration and, if so, whether tau physically
interacts with these proteins in the fly eye or brain. Furthermore,
the expression of tau mutants unable to bind these interactors
may provide more definitive evidence of the role of such
interacting proteins in mediating tau-induced cell-cycle activa-
tion. We, and other groups, have successfully made mutant tau
constructs and expressed them in flies to elucidate various
aspects of tau pathobiology [44,46]. While these studies would
be significant if fruitful, they do rely on limited candidate-based
testing based on in vitro tau–protein interactions, or on
predictions of potential tau interactors based on modular
domains that may not hold true in vivo. Unbiased genetic
screens and protein interaction studies, such as yeast-2-hybrid
or immunoprecipitation in conjunction with mass spectrometry,
may represent powerful alternative approaches. In addition,
libraries for many modular domains now exist. It may be
worthwhile to test tau for binding in these libraries and to verify
interesting candidates for their ability to mediate tau-induced
cell-cycle activation in vivo.
Finally, the ability of multiple and diverse insults to mediate
neuronal cell-cycle re-entry would imply that the ability to
induce cell-cycle activation is not specific to tau phosphoryla-
tion [6]. Indeed, cell-cycle mechanisms have been implicated in
PD also [81–83]. While we did not find evidence for cell-cycle
activation in tau-independent models of neurodegeneration
(MJD and PD), other Drosophila models, notably recentmodels of AD based on ectopic beta-amyloid expression [84–
87], remain to be tested for genetic modification by cell-cycle
and mitogenic signaling modulation.
5. Conclusion
The idea, proposed more than a decade ago, that ectopic cell-
cycle activation in neurons might lead not to their proliferation,
but to their demise, is an intriguing one.A number of investigators
subsequently identified aberrant expression of cell-cycle markers
in human postmortem tissue from a variety of neurodegenerative
diseases, most notably AD and other tauopathies, thus establish-
ing this idea as one of potential clinical relevance. Further work in
cell-culture systems provided mechanistic insights into how cell-
cycle mediators might transduce apoptotic signals.
Recent investigations in a Drosophila tauopathy model have
complemented these studies, principally by enabling a thorough
genetic substantiation of the idea that cell-cycle activation
mediates neuronal death in vivo. In the tauopathy model, inroads
have been made in identifying signaling pathways, including
TOR kinase signaling, that may mediate aberrant mitogenic
signals in the human disease. These investigations raise the
possibility that TOR and the cell cycle are therapeutic targets in
human tauopathies, including AD, a hypothesis that is now
amenable to testing in mouse tauopathy models. Powerful ge-
netic methods available in flies, including the ability to express
mutant tau constructs, have enabled mechanistic insights to be
made. For example, the experiments investigating the epistasis
of tau phosphorylation to cell-cycle activation suggest that tau
phosphorylation is upstream of cell-cycle activation [46].
For all the progress that has been made in human tissue,
mammalian cell-culture and Drosophila model systems, funda-
mental and important questions remain. These include whether or
not a coordinated cell-cycle activation, or simply certain cell-
cycle activators, is required to mediate neuronal death; whether
ectopic neuronal cell-cycle activation is always sufficient to
mediate neuronal apoptosis; andwhether cell-autonomous versus
non cell-autonomous factors play a role in cell-cycle-mediated
neurodegeneration. Finally, the relationship of cell-cycle activa-
tion to other signaling pathways, including those related to cell-
cycle checkpoints and aging, remain unclear in vivo.
It is intriguing that there may be a significant mechanistic
connection between oncogenesis and neurodegeneration, two
major pathologies associated with aging. With versatile and
powerful tools available, Drosophila models may be superbly
suited to gauge the depth of this connection, and its basis.
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